have evaluated, in the operating room to detect early hypeor hyperglycemia would be helpful. We conclude that the Accu-Check II and Glucometer H offer adequate precision and accuracy for such use.
We thank Eastman Kodak for providing the necessaryslides for these studies.
Assay of metanephrines (normetanephrine and metanephrine, NM and M, respectively) in urine for diagnosis and characterization of pheochromocytoma or other neural crest tumors is well established (1). These determinations may also be valuable in patients with depressive disorders (2) or essential hypertension (3) , in which cases metanephrines are evaluated in conjunction with data on other catecholamine metabolites.
A 57-year-old man with a history of essential hypertension was referred to the laboratory. Results of the laboratory tests were within normal limits except for a major increase The procedure we used included sample clean-up with a commercially available cation-exchange column developed for determining urinary M and NM (Bio-Rad Labs., Richmond, CA). For chromatographic separation, we used a Nova-Pak C18 column, 5-sm (diameter) particle size, and a flow rate of 1 mL/min. The detection wavelength was 200 nm.
The mobile phase consisted of 890 mL of distilled water, 110 mL of acetonitnile, and one vial of a counter-paired ion"PIC" B8 (Waters). For the internal standard we used 3-methoy-4-hydroxybenzylamine hydrochloride. Figure 1 illustrates a typical chromatogram obtained for NM, M, and internal standard. The pattern for the patient's sample was similar, but with a higher concentration of NM.
Because these infrequently noted increases can cause considerable confusion, particularly when they involve patients who have had or are suspected of having hypertension, weevaluated the possibility of interference from drugs.
We therefore repeated the analysis, supplementing, at therapeutic concentrations, normal urine with bromazepam (Lexotan#{174}), sulpiride (Dogmatyl#{174}), viloxazine (Vivalan#{174}), and guanfacine (Estulic#{174}). All these drugs were being taken by the patient when he was referred to us. The resulting peak heights for NM, M, and the internal standard (IS) in the presence of these drugs were as follows: The "Toxilab" thin-layer chromatographic drug-screening system is used extensively to detect drugs in biological fluids. Toxilab readily identifies phenylpropanolamine in urine. In view of the above-described abuse of d-norpseudoephedrine, we examined the ability of the Toxilab system to distinguish phenylpropranolamine from its congener d- . mp 77-78 #{176}C1 was 224 mg (92.7%) . Phenylpropanolamine and d-norpseudoephedrine were analzyed separately by the Toxilab procedure (4). The migration and color characteristics of phenylpropanolamine were within the specifications of the Toxilab system, but were indistinguishable from those of d-norpseudoephedrine. The sympathomimetic-ainine differentiation procedure also failed to distinguish between the two drugs. Phenylpropanolamine (5) and d-norpseudoephedrine (6) are excreted in human urine unchanged. Thus, the Toxilab system cannot distinguish between these two drugs. Abuse of and overdose with dnorpseudoephedrine may therefore be erroneously attributed to phenylpropranolamine when Toxilab is the drugdetection system being used.
